Complix

Activities: Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Merck & Co enters Alphabodies agreement with Complix to develop cancer treatments

Complix will receive upfront fees, research funding, and milestone payments of up to US$280m
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

How to turn peptides into drugs

Big Pharma companies have shown a real interest in peptides recently, but while they may make good starting points peptides rarely have the optimal properties to make successful drugs. Dr Sarah Houlton describes some of the routes being investigated to overcome these challenges
Subscribe now